Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,309.60
(
-1.73%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.19
(
3.60%
)
Bitcoin
69,952.99
(
0.08%
)
News Focus
News Focus
Post# of 257263
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

turtlepower

Send PM Follow Ignore
Followers 1
Posts 1114
Boards Moderated 0
Alias Born 04/07/2009

turtlepower

Re: jq1234 post# 148098

Monday, 09/03/2012 6:30:40 PM

Monday, September 03, 2012 6:30:40 PM

Post# of 257263
EXEL-

Cabo is a lot better bet on Xtandi/Zytiga failure because data showed there wasn't much difference in Xtandi/Zytiga treated vs chemo treated - this is an important factor to me in EXEL valuation.



Was that proven with the 60 mg dose, which is what they are using for COMET-1? The previous data for xtandi/zytiga failures is with the 100 mg dose.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today